Circulating tumour cells may predict late recurrence in HR-positive breast cancer patients

Dec 9th, 2017 - Dr Joseph Sparano speaks at a SABCS 2017 press session about how his findings show that a single positive CTC assay result five years after diagnosis provides independent prognostic information for late recurrence.

New Data on the Second Line Treatment of HER2+ Breast Cancer

Dec 11th, 2017 - New Data on the Second Line Treatment of HER2+ Breast Cancer From SABCS 2017 Interview with Jame Abraham MD, FACP Interview by Farzanna S Haffizulla MD, FACP, FAMWA

Postmenopausal women who lose weight may have reduced breast cancer risk

Dec 9th, 2017 - Prof Rowan Chlebowski speaks at a SABCS 2017 press session about how postmenopausal women who lose weight may have reduced breast cancer risk.

Rowan T. Chlebowski, MD, PhD, on Weight Loss and Breast Cancer Risk: Results From the Women’s Health Initiative

Dec 7th, 2017 - Rowan T. Chlebowski, MD, PhD, of the City of Hope National Medical Center, discusses 11-year followup results that showed a significantly lower breast cancer incidence among women with a greater than 5% weight loss (Abstract GS5-07).

Sherene Loi, MD, PhD, and Roberto Salgado, MD, PhD, on HER2+ Metastatic Breast Cancer: Results From the PANACEA/KEYNOTE 014 Trial

Dec 8th, 2017 - Sherene Loi, MD, PhD, and Roberto Salgado, MD, PhD, both of the Peter MacCallum Cancer Centre, discuss study findings on pembrolizumab and trastuzumab in patients with trastuzumab-resistant disease (Abstract GS2-06).

Adjuvant trastuzumab did not improve outcomes for patients with HER2-low breast cancer

Dec 7th, 2017 - Dr Fehrenbacher speaks at a SABCS 2017 press session about data from the randomised, phase III NSABP-B-47 clinical trial.

HER2low invasive breast cancer: Trastuzumab offers no improvement for invasive disease free survival

Dec 7th, 2017 - Dr Fehrenbacher speaks with ecancer at SABCS 2017 about a phase III trial of adjuvant chemotherapy with or without trastuzumab for HER2low invasive breast cancer.

Wolfgang Janni, MD, PhD, on Early Breast Cancer and Bisphosphonate Treatment: Results From the SUCCESS A Trial

Dec 6th, 2017 - Wolfgang Janni, MD, PhD, of Ulm University, discusses study findings that showed extended adjuvant bisphosphonate treatment over 5 years in early breast cancer does not improve disease-free and overall survival when compared with 2 years of treatment (Abstract GS1-06).

The SOFT trial: Comparing adjuvant tamoxifen with ovarian function suppression via exemestane to tamoxifen alone

Dec 8th, 2017 - Dr Gini Fleming speaks with ecancer at SABCS 2017 about the outcomes of the SOFT trial comparing adjuvant tamoxifen with ovarian function suppression via exemestane to tamoxifen alone.

Management of Locoregional Recurrence in Breast Cancer

Dec 14th, 2017 - William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago, reviews the management of locoregional recurrence in breast cancer.

Breast cancer therapy resistance mediated by FGFR amplification

Dec 9th, 2017 - Dr Luigi Formisano speaks with ecancer at SABCS 2017 about breast cancer therapy resistance mediated by FGFR amplification.

Updates on the Management of Male Breast Cancer

Dec 12th, 2017 - N. Lynn Henry, MD, PhD, of the University of Utah Huntsman Cancer Institute, highlights four abstracts investigating the use of hereditary gene panels and methods to predict prognosis in male breast cancer.

The role of axiliary node dissection in modern breast cancer surgery

Dec 9th, 2017 - Dr Viviana Galimberti speaks with ecancer at SABCS 2017 about the role of axillary node dissection in modern breast cancer surgery.

Preserving Fertility in Breast Cancer Patients After Chemotherapy

Dec 12th, 2017 - Kathryn J. Ruddy, MD, MPH, of the Mayo Clinic in Rochester, Minnesota, discusses four abstracts on preserving fertility in premenopausal breast cancer patients treated with chemotherapy

For Low-Level HER2 Breast Cancer, Trastuzumab Is a No-Go

Dec 9th, 2017 - Although the study didn't turn out as hoped, NSABP B-47 will help inform the decision of whether patients with low-level HER2 breast cancer should receive trastuzumab.

Precision Imaging in Breast Cancer

Dec 12th, 2017 - Maxine S. Jochelson, MD, of Memorial Sloan Kettering Cancer Center in New York, discusses four posters on the use of mammography, magnetic resonance imaging (MRI), and radiomics as biomarkers for treatment response

Anastrozole duration for post-menopausal breast cancer patients after 5 years of endocrine therapy

Dec 9th, 2017 - Prof Michael Gnant speaks with ecancer at SABCS 2017 to discuss the outcomes of a multi-centre phase III randomised trial of 2 or 5 years of anastrozole for post-menopausal breast cancer patients after 5 years of endocrine therapy.

Acupuncture Reduced AI-Related Joint Pain in Early-Stage Breast Cancer

Dec 7th, 2017 - Undergoing acupuncture significantly reduced joint pain related to treatment with aromatase inhibitors in postmenopausal women with early-stage breast cancer.

Acupuncture May Reduce Joint Pain Caused by Aromatase Inhibitor Treatment

Dec 7th, 2017 - Acupuncture significantly reduced joint pain for postmenopausal women with early-stage breast cancer receiving treatment with an aromatase inhibitor compared with both sham acupuncture and no treatment, according to data from the randomized, phase III SWOG S1200 trial presented by Hershman et al at the 2017 San Antonio Breast Cancer Symposium (Abstract GS4-04).

Acupuncture significantly reduces joint pain for breast cancer patients

Dec 7th, 2017 - In the largest, most rigorous study of its kind, acupuncture was found to significantly reduce the debilitating joint pain experienced by tens of thousands of women each year while being treated for early stage breast cancer, according to SWOG research results to be announced at a December 7 press conference at the San Antonio Breast Cancer Symposium.